Cyclosporine A (CsA) may increase the incidence of thrombotic events, but whether tacrolimus (Tc) has such effects is still unclear. The serotonergic system has been linked to the thrombotic effects of CsA, but a direct effect of CsA on serotonin-induced platelet aggregation has not been demonstrated because of methodological difficulties. We measured the effects of CsA and Tc on serotonin-induced platelet aggregate formation by particle counting using light scattering. CsA and Tc both enhanced serotonin-induced formation of small platelet aggregates, however, neither CsA nor Tc affected aggregation induced by high or low concentrations of ADP, with or without addition of a serotonin receptor antagonist. Both CsA and Tc enhance platelet aggregation induced via the serotonin pathway.
Cyclosporine A (CsA) has an important role in the prevention of graft-versus-host disease (GVHD) after bone marrow transplantation (BMT). However, CsA sometimes is associated with thrombotic complications, such as thrombotic microangiopathy (TMA). 1 CsA is known to inhibit prostacyclin release from vascular endothelial cells and to enhance thromboxane A 2 release from renal cells; 2 these effects may mediate CsA-associated thrombotic events. CsA also may increase amounts of circulating transforming growth factor (TGF-␤), which in turn is believed to increase the immunosuppressive effect, as well as, cytotoxicity of CsA. 3 In accord with these observations, CsA is suspected to cause thrombotic complications after BMT. Several reports have suggested that CsA enhances platelet function [4] [5] [6] [7] [8] [9] supporting the likelihood of CsA-induced TMA following BMT.
To prevent GVHD, Tacrolimus (Tc) is given to patients undergoing BMT in a manner similar to CsA. Unlike CsA, however, Tc has the inhibitory effect of platelet function, 8 and Tc is considered to suppress thrombosis. However, Tcrelated thrombotic thrombocytopenic purpura (TTP) after BMT has also been reported, 10 and the mechanism remains to be clarified.
The peripheral serotonergic system may be involved in the thrombotic effect of CsA;
7 the effects of CsA on serotonin-induced platelet activation need to be distinguished from effects on other pathways leading to thrombus formation in order to define the pro-thrombotic effect of CsA in the post-BMT setting. However, slight activation of certain platelet function parameters, such as serotonin-induced platelet aggregation, has been difficult to detect using the conventional method of Born.
11 A recently developed method for studying platelet aggregation by a particle counting technique using light scattering [12] [13] [14] [15] [16] can detect subtle changes in platelet activation.
To obtain further information on the influence of CsA and Tc on thrombotic tendencies after BMT, we examined the effects of these agents on serotonin-induced platelet aggregation evaluated using particle counting by light scattering.
Materials and methods

Chemicals
CsA and Tc, respectively, were purchased from Novartis Pharma (Tokyo, Japan), and Fujisawa Pharmaceutical (Osaka, Japan). Serotonin (5-hydroxytryptamine) and adenosine diphosphate (ADP) were obtained from Sigma Chemical (St Louis, MO, USA). Sarpogrelate powder was supplied by Mitsubishi-Tokyo Chemical (Tokyo, Japan). Each chemical was dissolved just before use in Tyrode's solution buffered by 10 mm N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfocic acid (Hepes).
Platelet preparation
Human platelets were obtained from healthy donors who had taken no medication for at least 10 days. Venous blood was drawn into 3.8% sodium citrate (1:9 v/v). Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were obtained by centrifugation of the citrated blood at room temperature for 10 min at 150 g and for 15 min at 3000 g, Bone Marrow Transplantation respectively. The platelet count in PRP was adjusted to 2 ϫ 10 11 /l with PPP.
Platelet aggregation
Platelet aggregation was monitored with an AG-10 aggregometer (Kowa, Tokyo, Japan), which determines the size and number of platelet aggregates based on particle counting using light scattering. [12] [13] [14] [15] [16] The principles of this method have been described previously. 12 A laser beam (675 nm) was passed through a platelet suspension, and the intensity of light scattering provided information on the number and size of aggregates. Data were recorded as a two-dimensional graph showing the change over time of total light intensity expressed as cumulative summation. The total light intensities of small and large aggregates were determined. Particles with an intensity of 25 to 400 mV represented small aggregates consisting of less than 100 platelets, and those with an intensity of 400 to 2048 mV represented large aggregates consisting of more than 100 platelets. It is reported that the primary aggregation, as detected by the conventional method, 11 represents the phase of small aggregate formation, and the secondary aggregation is the phase in which small aggregates fuse to form larger aggregates. 15 Therefore, weak aggregation is observed as a reaction in which only small aggregates are formed, and small aggregates are fused to large aggregates as the grade of platelet activation strengthens. 12, 16 In platelet aggregation by a strong agonist, such as thrombin, both small and large aggregates are simultaneously observed with a reaction start. It is thought that this method is more sensitive than the conventional method, and it is especially useful for observing a weak reaction. 12, 15 PRP (180 l) was placed in a cuvette and incubated for 3 min at 37°C with 20 l of CsA or Tc solution (final concentration range, 0.1 to 10 g/ml) or Tyrode's solution for the control during rotation at 1000 r.p.m. Subsequently, 22 l of serotonin (final concentration, 1.0 m), or ADP (final concentration, 0.1 or 0.4 m) was added, and formation of small and large aggregates were monitored for 10 min.
The quantitative estimation was performed by determining the area under the curve (AUC) representing the sum of the light scattering intensity. Since it is thought that AUC shows the intensity of overall aggregate formation, it is considered more appropriate for AUC to estimate platelet reaction rather than peak aggregation which shows a temporary reaction. The grade of platelet aggregation using AUC is also shown in a previous report. 16 
Statistical analysis
Numerical data are expressed as the mean Ϯ s.d. For comparisons between groups, the Mann-Whitney U test was used. Probability values less than 5% were considered to indicate significance.
Results
The addition of only CsA (10 g/ml) to PRP induced no aggregate formation (Figure 1a) . When serotonin was used as the agonist initiating platelet aggregation, only transient small-aggregate formation was observed (Figure 1b) . This occurred immediately after addition of serotonin to PRP, and larger aggregates were not formed. On addition of CsA, serotonin-induced formation of small aggregates showed a dose-dependent increase (Figure 1c-e) . When mean AUC values resulting from addition of 0.1, 1 and 10 g/ml of CsA additions were compared (n ϭ 5 experiments), significant increments were found at 1 and 10 g/ml of CsA (Figure 2) .
Tc also increased serotonin-induced formation of small aggregates, and significant increments were observed at final Tc concentrations greater than 0.1 g/ml (Figure 2 ). On the other hand, even if only Tc was added to PRP, no aggregate formation was observed as seen with the addition of CsA only (data not shown).
When 1 m of ADP was used to induce platelet aggregation, small aggregates formed first, followed by the larger aggregate formation (Figure 3a) . However, no significant change occurred with the addition of CsA even at a final concentration of 10 g/ml (Figure 3b ). To better understand the difference in the effect of CsA on serotonin-and ADP-induced platelet aggregate formation, sarpogrelate was used as a specific antagonist at the S 2 -serotonergic receptor on the platelet membrane. When 10 m of sarpogrelate was added to PRP, small aggregate formation was continued until the end of observation and larger aggregate formation was transient (Figure 4a ). No change in this reaction occurred with addition of CsA (Figure 4b ). When a low concentration of ADP (0.4 m) was used as the agonist, only transient small aggregate formation was observe as occurred with serotonin (Figure 5a ), and no change was induced by addition of CsA (Figure 5b) . Addition of Tc instead of CsA also had no effect on this ADP-induced platelet aggregate formation (data not shown).
Discussion
To confirm the effects of CsA and Tc on platelet function related to the serotonergic system, serotonin-induced platelet aggregate formation was observed by particle counting using light scattering. Both CsA and Tc dose dependently enhanced serotonin-induced platelet small aggregate formation in the 0.1 to 10 g/ml concentration range. On the other hand, CsA and Tc had no effect on platelet aggregate formation induced by ADP at 1 m. We first considered the possibility that CsA did not affect platelet aggregate formation induced by 1 m ADP because this concentration of ADP induces platelet reactions more strongly than serotonin. To investigate this possibility, the serotonin antagonist sarpogrelate was added in addition to ADP at 1 m; in another experiment, a low concentration (0.4 m) of ADP was used. In these experiments, CsA still had no effect on ADP-induced platelet aggregation. Sarpogrelate is a selective S 2 -serotonergic receptor antagonist that inhibits S 2 -potentiated platelet aggregation. 17 In the absence of sarpogrelate, ADP at 1 m induced the small aggregate formation followed by larger aggregate formation (Figure 3) , suggesting that small aggregates fuse to form larger aggregates. When sarpogrelate was added to PRP together with 1 m of ADP, small aggregates were consistently seen, with larger aggregate formation occurring only transiently ( Figure 3) . Therefore, in ADP-induced platelet aggregation, serotonin may function by enhancing fusion of aggregates. With the effect of serotonin excluded by adding sarpogrelate, CsA had no effect on ADP-induced platelet aggregation, suggesting that CsA affects only the serotonin pathway of platelet aggregation. Furthermore, CsA had no effect on small aggregate formation induced by a low concentration (0.4 m) of ADP ( Figure 5 ), suggesting that the lack of a CsA effect on ADP-induced platelet aggregation was not a result of a stronger ADP-induced reaction relative to serotonin-induced aggregation.
Reis et al 9 reported that platelet activation was increased in rats with CsA-induced hypertension, and pointed out that peripheral serotonergic system might be involved. Understanding the platelet reaction induced by serotonin, requires distinguishing effects of serotonin on platelet activation from those involving other pathways. Mysliwiec et al 7 reported that serotonin augment action of ADP-induced platelet aggregation was enhanced by injection of CsA in a rat model of uremia. Although these authors sought to emphasize that CsA enhanced serotonin-induced platelet activation, they observed platelet aggregation using the conventional method of Born, 11 which could not show serotonin-induced platelet aggregation in isolation. Particle counting using light scattering, [12] [13] [14] [15] [16] which we used in the present study, permits direct monitoring of the serotonininduced platelet activation, and the results seen with this method clearly show enhancement of serotonin-induced platelet aggregation.
The effect of Tc on platelet function has been a matter of controversy; previous reports have shown various effects of Tc on platelet function. Muraki et al 8 reported that Tc significantly inhibited both platelet reactivity and coagulation in rats. While Mysliwiec et al 7 reported that Tc had no effect on serotonin blood content or platelet aggregability. Both of these reports, then, would support changing treatment from CsA to Tc when TMA occurred in patients with BMT. 18 On the other hand, the thrombotic thrombocytopenic purpura (TTP) has occurred after BMT associated with Tc. 10 In the present study, we found that Tc enhances serotonin-induced platelet aggregation similarly to CsA.
The concentrations of CsA and Tc used in the experiments should be related to the therapeutic levels achieved in vivo. When an intravenous injection of CsA is given at the clinical dose, it is thought that CsA concentration in blood reaches 0.5-1.0 g/ml.
19 Therefore, the CsA concentration used in this experiment is mostly correlated with the level in the blood used in actual medical treatment. However, the concentration of Tc in the circulating blood under medical treatment is 0.01-0.05 g/ml, 20 and the concentration of Tc used in this experiment is high compared with this. Although the same tendency was observed using Tc in a low concentration of less than 0.5 g/ml in the preliminary experiment, this result was not statistically significant. This point is probably related to previous reports on the influence of Tc on platelets having been varied until now. However, when Tc concentration in circulating blood rises abnormally, it is assumed that Tc may activate platelets like CsA in vivo.
The mechanism on the surface membrane or intracellular reaction of platelets whereby CsA and Tc might mediate this effect has not been clarified. Fishman et al 5 reported that CsA may increase fibrinogen binding by altering GPIIb-IIIa on the platelet membrane, and intracellular calcium concentration rises as a consequence. Another report showed that there is no change in intracellular thromboxane A 2 concentration although protein kinase C is activated. 6 We can only speculate that the serotonergic system is involved in the effect of CsA and Tc from the results obtained in this study. As the enhancement of platelet aggregation by CsA was inhibited by the addition of sarpogrelate, CsA may have a certain influence on serotonergic receptors on the platelet surface. It is also implied that CsA and Tc stimulate the release of serotonin from platelet granules. Serotonin is thought to be participating in at least part of this reaction, supporting the results of previous reports in which CsA was assumed to activate serotonin-related platelet activation. 7, 9 Although the details of the mechanisms remain to be clarified, Tc as well as CsA may promote thrombotic events in patients treated with BMT.
